ANDA 217319, held by Chartwell Rx. Sevelamer Carbonate.
As of Nov 16, 2026, ANDA 217319 (Sevelamer Carbonate), held by Chartwell Rx, was first approved by FDA on Mar 2, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 2, 2023 | Original application | Approved | None posted |
| Sevelamer Carbonate800MG/PACKET · for suspension;oral | Sevelamer Carbonate | Rx |
| Sevelamer Carbonate2.4GM/PACKET · for suspension;oral | Sevelamer Carbonate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters